EM-T3Expert Opinion on Drug Safety2021-05-28第 20 卷第 8 期,949-957高影响力 · 前 10%
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis